Moors & Cabot, Inc. Karyopharm Therapeutics Inc. Transaction History

Moors & Cabot, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$2.48 - $5.93 $23,188 - $55,445	-9,350 Reduced 43.39%	12,200 $41,000
Q4 2022 Feb 06, 2023	BUY	$2.48 - $5.93 $992 - $2,372	400 Added 1.89%	21,550 $73,000
Q2 2022 Aug 08, 2022	SELL	$4.15 - $8.37 $1,660 - $3,347	-400 Reduced 1.86%	21,150 $95,000
Q4 2021 Feb 14, 2022	BUY	$5.21 - $8.61 $2,084 - $3,444	400 Added 1.89%	21,550 $139,000
Q3 2021 Dec 08, 2021	SELL	$4.45 - $10.63 $88,332 - $211,005	-19,850 Reduced 48.41%	21,150 $123,000
Q3 2021 Nov 05, 2021	BUY	$4.45 - $10.63 $99,457 - $237,580	22,350 Added 119.84%	41,000 $49,000
Q2 2021 Aug 10, 2021	SELL	$8.11 - $11.11 $2,433 - $3,333	-300 Reduced 1.58%	18,650 $192,000
Q1 2021 May 12, 2021	BUY	$9.85 - $17.69 $41,370 - $74,298	4,200 Added 28.47%	18,950 $199,000
Q4 2020 Feb 11, 2021	BUY	$14.15 - $17.19 $208,712 - $253,552	14,750 New	14,750 $226,000

59.6M

547K

67K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $47.9M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.